<DOC>
	<DOCNO>NCT01337492</DOCNO>
	<brief_summary>Patients either histological confirmation clinical diagnosis candidate orthotopic liver transplant ( OLT ) receive Sorafenib 400mg 2 x day ( BID ) neoadjuvant ( bridge ) treatment transplant . If patient progress fall outside Milan criterion sorafenib patient treat per physician 's discretion use local therapy . Patient follow 30 day orthotopic liver transplant ( OLT ) .</brief_summary>
	<brief_title>Pilot Study Sorafenib Bridge Orthotopic Liver Transplantation ( OLT )</brief_title>
	<detailed_description>Primary objective : â€¢ To evaluate safety ( include possible surgical complication ) feasibility use sorafenib neo-adjuvant ( bridge therapy ) prior orthotopic liver transplant ( OLT ) . The primary goal pilot study assess safety feasibility treat HCC patient sorafenib prior OLT , determine number patient experience grade 4 hemorrhage bleed post-operatively . To achieve goal 2-stage accrual design use maximum accrual goal 10 patient . Initially 5 patient enter on-study . If one patient experience grade 4 hemorrhaging/bleeding follow OLT trial close sorafenib consider safe and/or feasible . If patient experience event 5 additional patient enrol . At end study sorafenib consider safe feasible set patient experience grade 4 hemorrhaging/bleeding follow transplant . With design , assume least 3 5 patient cohort undergo OLT , likelihood stop early &lt; .04 underlie risk hemorrhages/bleeding low ( &lt; 5 % ) whereas &gt; .42 chance early termination risk substantial ( e.g . &gt; .20 likelihood dose limit toxicity &gt; .30 likelihood &gt; grade 4 hemorrhages/bleeding ) . Overall likelihood accept accept sorafenib safe feasible &gt; .84 , &lt; .16 , respectively condition . Secondary objective : - Drop rate - Time progression prior orthotopic liver transplant ( OLT ) - Waiting time .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Inclusion criterion : Age &gt; 18 year old Confirmation diagnosis Hepato Cellular Carcinoma ( HCC ) within Milan criterion await liver transplant go evaluation Liver Transplant . Either histological confirmation clinical diagnosis American Association Study Liver Diseases ( AASLD ) criterion ( see Appendix 1 ) cirrhotic subject require . For subject without cirrhosis histological confirmation mandatory . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Child Pugh A B ( Total point 7 allow See appendix score system ) . ( ONLY 4 patient Child Pugh B7 allow . ) Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; 8.5 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 60,000/mm3 Total bilirubin &lt; 1.5 time Upper Limits Normal ( ULN ) ALT AST &lt; 2.5 time Upper Limits Normal ( ULN ) ( &lt; 5 x ULN patient liver involvement ) Creatinine &lt; 1.5 time Upper Limits Normal ( ULN ) Women childbearing potential must 2 negative serum pregnancy test perform . The first test within 710 day prior start treatment . The second test within 24 hour prior start treatment . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least three month last administration sorafenib . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . Exclusion Criteria Cardiac disease : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Prior use sorafenib Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection . Active clinically serious infection &gt; CTCAE Grade 2 except Except Hepatitis B ( HBV ) Hepatitis C ( HCV ) Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis Major surgery , open biopsy significant traumatic injury within 4 week first study drug . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Orthotopic Liver Transplant</keyword>
</DOC>